+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis



An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis



European Journal of Cancer 40(9): 1314-1319



Oropharyngeal candidosis is a frequent infection in cancer patients who receive cytotoxic drugs. In this study, the efficacy, safety and tolerance of fluconazole and itraconazole were compared in non-neutropenic cancer patients with oropharyngeal candidosis. Of 279 patients who were randomized between the two treatment groups, 252 patients were considered to be eligible (126 in each group).

(PDF emailed within 0-6 h: $19.90)

Accession: 004037183

Download citation: RISBibTeXText

PMID: 15177489

DOI: 10.1016/j.ejca.2004.03.003


Related references

Safety and efficacy of single-dose fluconazole compared with a 7-day regimen of itraconazole in the treatment of AIDS-related oropharyngeal candidiasis. Journal of International Medical Research 26(3): 159-170, 1998

Fluconazole versus itraconazole in therapy of oropharyngeal candidiasis in cancer patients: a prospective comparative randomized trial. Journal of ChemoTherapy 7 Suppl 4: 204-205, 1995

An open multicentre study of the efficacy and safety of a single dose of fluconazole 150 mg in the treatment of vaginal candidiasis in general practice. British Journal of Clinical Practice 44(6): 219-222, 1990

Multicentre comparative study between fluconazole and itraconazole in the treatment of vulvovaginal candidiasis. Revista Brasileira de Medicina 59(4): 244-249, 2002

Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in aids patients. Brazilian Journal of Infectious Diseases 5(2): 60-66, 2001

Fluconazole in therapy of candidiasis of the oropharyngeal space in patients with HIV infection. Results of an open multicenter study of assessing the effectiveness and tolerance of fluconazole. Medizinische Klinik 86(10): 508-511, 1991

Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis. Mycoses 39 Suppl 1: 102-106, 1996

Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. Aids Research and Human Retroviruses 15(16): 1413-1417, 1999

Fluconazole and itraconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against isolated yeasts from HIV positive patients with oropharyngeal candidiasis. Igiene Moderna 111(4): 417-429, 1999

An EORTC IFICG phase III randomized study comparing Fluconazole to Itraconazole in non neutropenic cancer patients with oropharyngeal candidiasis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 594, 1998

A Double-Blind Comparison of Itraconazole Oral Solution and Fluconazole Capsules for the Treatment of Oropharyngeal Candidiasis in Patients with Aids. Clinical Infectious Diseases 26(6): 1368-1373, 1998

A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clinical Infectious Diseases 26(6): 1368-1373, 1998

Multicentre open randomised comparative study on efficacy and safety of topical fluconazole 0.5% vs. econazole lipogel 1% in the treatment of localized dermatomycoses. Giornale Italiano di Dermatologia e Venereologia 134(3): 263-269, 1999

Efficacy of fluconazole and itraconazole in the treatment of oral candidiasis in HIV patients. Acta Tropica 80(2): 151-154, 2001

Efficacy and safety of the topical formulation of fluconazole 0.5% (gel containing an oil emulsion/water o/w) in the treatment of dermatomycoses with localized lesions. Results of a multicentre, open, non-comparative study. Giornale Italiano di Dermatologia e Venereologia 134(1): 61-65, 1999